الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 107 |  |  |
| | | from | 107 | | |
Abstract
Chronic infection with hepatitis C virus (HCV) is a major healthcare problem. Egypt faces the highest incidence rate in the world, as nearly seven out of a thousand Egyptians acquire HCV infections every year.
A substantial improvement in response rates of antiviral therapy for chronic hepatitis C (CHC) has been achieved over the last decade.
The addition of Sofosbuvir to ribavirin has resulted in improved hepatitis C virus (HCV) eradication rates as the sustained virologic response rates have been improved from around 5% with interferon di-therapy in the early 90s to 95% today.
Sexual dysfunction was reported as one of the extra-hepatic manifestation and as a side effect of the combined therapy, it refers to a difficult experience by an individual or a couple during any stage of normal sexual activity, including desire, arousal or orgasm.
Our study aimed to evaluate the effect of antiviral combination therapy on sexual function of male patients before, during and after treatment.
Our study was conducted on 200 male married patients “100 male patients who treated with [Sovaldi® 400mg/d + Daclinza®] for 12 weeks “easy to treat group” & 100 patients treated with [Sovaldi® 400mg/d + Daclinza® 60mg/d + Ribavirin® 600mg/d] for 12 weeks “difficult to treat group” , age ranged from 18-48 years recruited random from unit of “National Committee for Control of Viral Hepatitis in Beni Suef General Hospital” under treatment with combination therapy.
We used IIEF with male patients (Rosen et al., 1997) to evaluate the sexual functions during therapy.
Statistical comparison between two groups revealed that there were no significant differences as age, occupation, married from, special habits, and demographic data.
The sum of our study is lack of sexual side effects for “Sofosbuvir + Daclatasvir” in group I. But, about the randomly recruited group II patients treated with “Sovaldi + Daclinza + Ribavirin”, all patients had ED before initiating therapy, rendering it impossible to detect further deterioration with therapy.